Caricamento...
IT-16 COMBINATION TREATMENT WITH DELTA24-RGD AND TEMOZOLOMIDE IMPROVES SURVIVAL AND AFFECTS INTRATUMORAL IMMUNE CELL SUBSETS IN A MURINE MALIGNANT GLIOMA MODEL
INTRODUCTION: The oncolytic adenovirus Delta24-RGD specifically lyses tumor cells and is currently tested in clinical phase I/II trials for recurrent glioma. We recently showed that the efficacy of Delta24-RGD is mainly dependent on an induced anti-tumor immune response. As known, TMZ has pronounced...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218232/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou258.14 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|